Cargando…
Mechanism and therapeutic implications of pomalidomide-induced immune surface marker upregulation in EBV-positive lymphomas
Epstein-Barr virus (EBV) downregulates immune surface markers to avoid immune recognition. Pomalidomide (Pom) was previously shown to increase immune surface marker expression in EBV-infected tumor cells. We explored the mechanism by which Pom leads to these effects in EBV-infected cells. Pom increa...
Autores principales: | Jaeger, Hannah K., Davis, David A., Nair, Ashwin, Shrestha, Prabha, Stream, Alexandra, Yaparla, Amulya, Yarchoan, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354044/ https://www.ncbi.nlm.nih.gov/pubmed/37463943 http://dx.doi.org/10.1038/s41598-023-38156-z |
Ejemplares similares
-
Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2
por: Shrestha, Prabha, et al.
Publicado: (2021) -
Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells
por: Davis, David A., et al.
Publicado: (2018) -
Regulation of the Dimerization and Activity of SARS-CoV-2 Main Protease through Reversible Glutathionylation of Cysteine 300
por: Davis, David A., et al.
Publicado: (2021) -
Regulation of the Dimerization and Activity of SARS-CoV-2 Main Protease through Reversible Glutathionylation of Cysteine 300
por: Davis, David A., et al.
Publicado: (2021) -
Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide
por: Davis, David A., et al.
Publicado: (2017)